BioXconomy | mRNA Could Change the Battle Against TB

15 September 2026

BioXconomy analysis

A BioXconomy analysis of a review in npj Vaccines highlighted both the potential and current limitations of mRNA platforms in overcoming the shortcomings of the BCG (Bacille Calmette-Guérin) vaccine in preventing TB.

Read the full analysis here.

Source: BioXconomy